Antineoplastic and Immunomodulating Agents - Tocilizumab Products - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
Customize your policy alerts
Sign up for Oscar Health Policy CG108 alerts
Get alerted when Policy CG108 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-benefit exceptions for non-preferred intravenous tocilizumab products and continued intravenous Tyenne use. It applies to members requesting physician-administered tocilumab products when preferred-product and subcutaneous formulation requirements may not be met.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.